BioArctic AB (publ) (BIOA-B.ST)
SEK 170.0
(-0.93%)
SEK 170.0
(-0.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 346.31 Million SEK | 124.93% |
| 2022 | 153.96 Million SEK | 582.33% |
| 2021 | -31.92 Million SEK | -363.7% |
| 2020 | 12.1 Million SEK | -94.22% |
| 2019 | 209.35 Million SEK | -63.18% |
| 2018 | 568.61 Million SEK | 304.88% |
| 2017 | 140.44 Million SEK | 33.28% |
| 2016 | 105.37 Million SEK | 153.47% |
| 2015 | 41.57 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 45.03 Million SEK | 64.34% |
| 2024 Q1 | 27.4 Million SEK | 153.57% |
| 2023 Q1 | 363.28 Million SEK | 3114.6% |
| 2023 Q4 | -51.15 Million SEK | -126.45% |
| 2023 Q2 | -12.82 Million SEK | -103.53% |
| 2023 Q3 | 193.37 Million SEK | 1608.02% |
| 2023 FY | 346.31 Million SEK | 124.93% |
| 2022 Q3 | 187.33 Million SEK | 1949.33% |
| 2022 FY | 153.96 Million SEK | 582.33% |
| 2022 Q4 | -12.05 Million SEK | -106.43% |
| 2022 Q2 | -10.13 Million SEK | 9.47% |
| 2022 Q1 | -11.19 Million SEK | 5.35% |
| 2021 Q2 | -6.04 Million SEK | -46.6% |
| 2021 Q1 | -4.12 Million SEK | 17.81% |
| 2021 Q4 | -11.82 Million SEK | -19.03% |
| 2021 Q3 | -9.93 Million SEK | -64.36% |
| 2021 FY | -31.92 Million SEK | -363.7% |
| 2020 Q3 | -115 Thousand SEK | 98.68% |
| 2020 Q4 | -5.01 Million SEK | -4260.87% |
| 2020 FY | 12.1 Million SEK | -94.22% |
| 2020 Q1 | 25.94 Million SEK | 375.97% |
| 2020 Q2 | -8.7 Million SEK | -133.57% |
| 2019 FY | 209.35 Million SEK | -63.18% |
| 2019 Q4 | 5.45 Million SEK | -23.69% |
| 2019 Q3 | 7.14 Million SEK | -95.63% |
| 2019 Q2 | 163.3 Million SEK | 388.21% |
| 2019 Q1 | 33.45 Million SEK | -92.84% |
| 2018 FY | 568.61 Million SEK | 304.88% |
| 2018 Q2 | 23.84 Million SEK | -8.86% |
| 2018 Q4 | 467.29 Million SEK | 810.77% |
| 2018 Q1 | 26.16 Million SEK | 9.32% |
| 2018 Q3 | 51.3 Million SEK | 115.13% |
| 2017 Q3 | 18.82 Million SEK | 15.31% |
| 2017 FY | 140.44 Million SEK | 33.28% |
| 2017 Q4 | 23.93 Million SEK | 27.14% |
| 2017 Q2 | 16.32 Million SEK | -36.98% |
| 2017 Q1 | 25.9 Million SEK | -72.5% |
| 2016 Q1 | 4.99 Million SEK | 0.0% |
| 2016 FY | 105.37 Million SEK | 153.47% |
| 2016 Q4 | 94.2 Million SEK | 7869.71% |
| 2016 Q3 | 1.18 Million SEK | 18.08% |
| 2016 Q2 | 1 Million SEK | -79.96% |
| 2015 FY | 41.57 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 315.525% |
| Ziccum AB (publ) | -23.28 Million SEK | 1587.233% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | -728.767% |
| Mendus AB (publ) | 28.48 Million SEK | -1115.702% |
| Genovis AB (publ.) | 54 Million SEK | -541.316% |
| Intervacc AB (publ) | -13.79 Million SEK | 2610.635% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -15851.958% |
| Active Biotech AB (publ) | -1.67 Million SEK | 20775.642% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -3376.031% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -1191.216% |
| Aptahem AB (publ) | 2.63 Million SEK | -13064.703% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 10223.268% |
| Kancera AB (publ) | -1.96 Million SEK | 17724.275% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -449662.338% |
| Fluicell AB (publ) | 1.73 Million SEK | -19826.18% |
| Saniona AB (publ) | 11.78 Million SEK | -2839.623% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 6867.97% |
| Biovica International AB (publ) | 6.87 Million SEK | -4935.873% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 1587.424% |
| AcouSort AB (publ) | 8.38 Million SEK | -4028.227% |
| Xintela AB (publ) | 78 Thousand SEK | -443896.154% |
| Abliva AB (publ) | -35.66 Million SEK | 1071.082% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 335.75% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -12237.62% |
| OncoZenge AB (publ) | 3000.00 SEK | -11543800.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 18043.886% |
| 2cureX AB (publ) | -37.48 Million SEK | 1023.832% |
| CombiGene AB (publ) | -21.29 Million SEK | 1726.613% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 81971.631% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 69.348% |
| Camurus AB (publ) | 1.58 Billion SEK | 78.088% |
| Corline Biomedical AB | 28.38 Million SEK | -1120.285% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 382.169% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 1106.297% |
| I-Tech AB | 27.56 Million SEK | -1156.319% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | -388.107% |
| Cyxone AB (publ) | 2.61 Million SEK | -13163.769% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -10076.815% |
| Biosergen AB | -456 Thousand SEK | 76046.711% |
| Cantargia AB (publ) | -3.45 Million SEK | 10135.265% |
| NextCell Pharma AB | -43.74 Million SEK | 891.615% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 3866.772% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -2987.076% |
| Nanologica AB (publ) | -76 Thousand SEK | 455780.263% |
| SynAct Pharma AB | -778 Thousand SEK | 44613.753% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 179538.86% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 2780.057% |
| Lipum AB (publ) | 53 Thousand SEK | -653328.302% |
| BioInvent International AB (publ) | 71.46 Million SEK | -384.624% |
| Alzinova AB (publ) | 19.87 Million SEK | -1642.563% |
| Oncopeptides AB (publ) | 36.29 Million SEK | -854.068% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -23571.378% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 2308880.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -20787.636% |
| Simris Alg AB (publ) | 2 Million SEK | -17155.456% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 9773.659% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | -878.628% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 33114.013% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -10953.846% |